Verified peer comparison

CI vs ABBV

The Cigna Group compared with AbbVie Inc.. This page compares both source-verified company profiles and does not introduce an unverified price target.

The Cigna Group

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

ABBV

AbbVie Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

CI: Managed Health Care

ABBV: Biotechnology

Upside lens

CI: Specialty pharmacy, care services and benefit-management scale can deepen relationships with health-plan clients. Growth in complex therapies can increase demand for specialty distribution, pharmacy and adherence services. Strong cash generation can support repurchases and debt reduction when operating targets are met.

ABBV: Continued Skyrizi and Rinvoq adoption is expanding AbbVie's immunology portfolio and replacing revenue lost after Humira's U.S. exclusivity expiry. Growth across Vraylar, Botox Therapeutic, the migraine portfolio, and Vyalev broadens AbbVie's growth base beyond immunology. Regulatory submissions, approvals, and key clinical data readouts expected over the next year could add indications and reinforce the post-Humira portfolio transition.

Risk lens

CI: New rules on rebates, spread pricing or transparency could reduce benefit-management profitability. Loss or repricing of large health-plan and employer contracts can create meaningful revenue volatility. Unexpected utilization can pressure the healthcare segment despite underwriting discipline.

ABBV: Humira revenue continues to contract after biosimilar entry, leaving execution on replacement growth products essential to the portfolio transition. Imbruvica declines are weighing on oncology, requiring growth from Venclexta, Elahere, and pipeline assets to offset the mature brand. U.S. drug-pricing policy, including the selection of Botox for Medicare negotiated prices beginning in 2028, could pressure future revenue and margins.